Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-12-10
2010-06-22
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388150, C530S387100, C530S387300, C424S130100, C424S141100, C424S145100
Reexamination Certificate
active
07741449
ABSTRACT:
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
REFERENCES:
patent: 4423147 (1983-12-01), Secher et al.
patent: 4902618 (1990-02-01), Berg
patent: 4973556 (1990-11-01), Bove et al.
patent: 6007805 (1999-12-01), Foster et al.
patent: 6458932 (2002-10-01), Novick et al.
patent: 6475983 (2002-11-01), Eid et al.
patent: 7087726 (2006-08-01), Chuntharapai et al.
patent: 2003/0166228 (2003-09-01), Chuntharapai et al.
patent: 0 633 931 (2003-05-01), None
patent: WO 92/18626 (1992-10-01), None
patent: WO 93/04699 (1993-03-01), None
patent: WO 93/20187 (1993-10-01), None
patent: WO 95/07716 (1995-03-01), None
patent: WO 95/24212 (1995-09-01), None
patent: WO 97/41229 (1997-11-01), None
patent: WO 98/24884 (1998-11-01), None
patent: WO 01/09187 (2001-08-01), None
patent: WO 02/43478 (2002-06-01), None
patent: WO 02/066649 (2002-08-01), None
Lederman et al. Molecular Immunology 28: 1171-1181, 1991.
Li et al. PNAS 77: 3211-3214, 1980.
Fishwild et al. (Nature Biotechnology, 1996 14:845-851.
Rudikoff et al. PNAS 1982 79:1979.
Klimka et al. British Journal of Caner 2000, 83:252-260.
Beiboer et al. J. Mol. Biol. 2000, 296:833-849.
MacCallum et al. J. Mol. Biol. 1996, 262:732-745.
Padlan et al. PNAS 1989, 86:5938-5942.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Barbas et al. PNAS 1995, 92:2529-2533.
International Search Report for PCT/US04/41777, dated Oct. 31, 2005.
Chen et al., EMBO J. 1993; 821-830.
Cook et al., J Biol Chem. 1996; 271:13448.
Cutrone and Langer, J Biol Chem. 2001; 276:17140.
Fishwild et al., Nature Biotechnology. 1996; 14:845-851.
Foulis et al., Lancet. 1987; 2:1423.
Hooks et al., Arthritis Rheum. 1982;25:396.
Lewerenz et al., J Mol Biol. 1998;282:585.
Lonberg et al., Nature. 1994;368(6474):856-859.
Mogensen et al., J Interferon Cytokine Res. 1999;19:1069.
Novick et al., Cell. 1994; 77:391.
Pestka et al., Ann Rev Biochem. 1987;56:727.
Santini et al., J Exp Med. 2000;191:1777.
Uze et al. Cell. 1990;225.
Blanco et al., Science 2001;294:1540-1543.
Pogue et al., J. Interferon & Cytokine Research 2004;24:131-139.
Santiago-Raber; J. Exp. Med 2003;197(6):777-788.
Bennett; J. Exp Med 2003;197(6);771-723.
Adolf et al., 1982, “Production of Monoclonal Antibodies to Human IFN-α and Their use For Analysis of the Antigenic Composition of Various Natural Interferons,”Journal of Cellular Physiology Supplement,vol. 2: p. 61-68.
Allen et al., 1982, “Analysis and Purification of Human Lymphoblastoid (Namalwa) Interferon Using a Monoclonal Antibody,”J. gen. Virol.,vol. 63: p. 207-212.
Allen et al., 1982, “Structure and properties of human interferon-α from Namalwa lymphoblastoid cells,”Biochem.J.,vol. 207: p. 397-408.
Amici et al., 2000, “Human erythocyte pyrimidine 5′-nucleotidase, PN-1, is identical to p36, a protein associated to lupus inclusion formation in response to α-interferon,”Blood,vol. 96, No. 4: p. 1596-1598.
Andzhaparidze et al., 1988, “Preparation of Hybridomas producing monoclonal antibodies against human interferon,”Acta Virol.,vol. 32, No. 6: p. 481-6.
Barasoain et al., 1989, “Antibodies Against a Peptide Representative of a Conserved Region of Human FN-α,”The Journal of Immunology,vol. 143, No. 2: p. 507-512.
Batteux et al., 1999, “FCgammaR11 (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus,”European Cytokine Network,vol. 10, No. 4: p. 509-514.
Bave et al., 2000, “The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN- α Inducer,”The Journal of Immunology,vol. 165: p. 3519-3526.
Belardelli et al., 1987, “Studies on the Expression of Spontaneous and Induced Interferons in Mouse Peritoneal Macrophages by Means of Monoclonal Antibodies to Mouse Interferons,”J. gen. Virol,vol. 68: p. 2203-2212.
Berthold et al., 1985, “Immunoassay for the Quantitation of Human Leukocyte Interferon,”Arzneim-Forsch./Drug Res.,vol. 35: p. 364-369.
Bigazzi, 2005, “Murine lupus induced by tetramethylpentadecane: an animal model of systemic human autoimmunity,”Clinical Immunology,vol. 114: p. 97-99.
Blank et al., 1999, “Identification of a linear epitope of interferon- α2b recognized by neutralizing monoclonal antibodies,”Eur. J. Biochem,vol. 265: p. 11-19.
Boyman et al., 2004, “Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α,”J. Exp. Med.,vol. 199, No. 5: p. 731-736.
Brunner et al., 1999, “Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the Evaluation of Clinical Change in Childhood-Onset Systemic Lupus Erythematosus,”Arthritis&Rheumatism,vol. 42, No. 7: p. 1354-1360.
Chen et al., 2000, “The relationship between Th1/Th2-type cells and disease activity in patients with systemic lupus erythematosus,”Chinese Medical Journal,vol. 113, No. 10: p. 877-880.
Chuntharapai et al., 2001, “Characterization and Humanization of a Monoclonal Antibody That Neutralizes Human Leukocyte Interferon: A Candidate Therapeutic for IDDM and SLE,”Cytokine,vol. 15, No. 5: p. 250-260.
Corzillius et al., 1999, “Responsiveness and sensitivity to change of SLE disease activity measures,”Lupus,vol. 8: p. 655-659.
Crow, 2003, “Interferon-α: A New Target for Therapy in Systemic Lupus Erythematosus?,”Arthritis&Rheumatism,vol. 48, No. 9: p. 2396-2401.
Csabayová et al., 1995, “Relativity of an Antigenic Homology Between Human Interferon-α1 and Interferon-α2c,”Immunological Investigations,vol. 24, No. 5: p. 787-793.
Dean et al., 2000, “Cytokines and systemic lupus erythematosus,”Ann Rheum Dis.,vol. 59: p. 243-251.
Exley et al., 1984, “A Comparison of the Neutralizing Properties of Monoclonal and Polyclonal Antibodies to Human Interferon Alpha,”J. gen. Virol.,vol. 65: p. 2277-2280.
Furukawa et al., 2005, “Animal models of spontaneous and drug-induced cutaneous lupus erythematosus,”Autoimmunity Reviews,vol. 4: p. 345-350.
Greensberg et al., 2005, “Interferon-α/β-Mediated Innate Immune Mechanisms in Dermatomyositis,”Ann Neurol,vol. 57: p. 664-678.
Gren et al., 1984, “Novel Human Leukocyte Interferon Subtype and Structural Comparison of Alpha Interferon Genes,”Journal of Intereron Research,vol. 4: p. 609-617.
Griffiths et al., 2005, “Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices,” vol. 19, No. 5: p. 685-708.
Grossberg et al., 2001, “The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay Systems,”Journal of Interferon and Cytokine Research,vol. 21: p. 729-742.
Grossberg et al., 2001, “The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction Unit,”Journal of Interferon and Cytokine Research,vol. 21: p. 743-755.
Hron et al., 2004, “Type I IFN Pro
Cardarelli Josephine M.
King David
Passmore David
Williams Denise
Witte Alison
Baker & Botts LLP
Gambel Phillip
Medarex Inc.
Wen Sharon
LandOfFree
Anti-interferon alpha antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-interferon alpha antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-interferon alpha antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158299